Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · see citing works

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636 · see citing works

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.

Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · see citing works

Role of osteoblasts in hormonal control of bone resorption—A hypothesis

Rodan, G. A., & Martin, T. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409454 · Cited by 982 · see citing works

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · see citing works

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · see citing works

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · see citing works

A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women

Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 770 · see citing works

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689 · see citing works

Bone Loss and Bone Size after Menopause

Ahlborg, H. G., Johnell, O., Turner, C. H., Rannevik, G., & Karlsson, M. K. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022464 · Cited by 647 · see citing works

The effect of a single dose of osteoprotegerin in postmenopausal women.

Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · see citing works

Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428 · see citing works

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391 · see citing works

Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin.

Redlich, K., Hayer, S., Maier, A., Dunstan, C. R., Tohidast‐Akrad, M., Lang, S., Türk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10097 · Cited by 285 · see citing works

Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282 · see citing works

Effects of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] on Cortical Bone in Postmenopausal Women With Osteoporosis

Zanchetta, J., Bogado, C. E., Ferretti, J., Wang, O., Wilson, M., Sato, M., Gaich, G. A., Dalsky, G. P., & Myers, S. L. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.539 · Cited by 241 · see citing works

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.

Lam, J. D., Nelson, C. A., Ross, F. P., Teitelbaum, S., & Fremont, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13890 · Cited by 205 · see citing works

Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.

Nakamura, M., Udagawa, N., Matsuura, S., Mogi, M., Nakamura, H., Horiuchi, H., Saito, N., Hiraoka, B. Y., Kobayashi, Y., Takaoka, K., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0717 · Cited by 191 · see citing works

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken, K., Leenheer, E. D., Shipman, C. M., Asosingh, K., Willems, A., Camp, B. V., & Croucher, P. I. (2003) · PubMed · Cited by 188 · see citing works

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.

Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187 · see citing works

Serum levels of osteoprotegerin increase with age in a healthy adult population.

Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187 · see citing works

The Anabolic Effects of Human Parathyroid Hormone (hPTH) on Rat Vertebral Body Mass Are also Reflected in the Quality of Bone, Assessed by Biomechanical Testing: A Comparison Study between hPTH-(1–34) and hPTH-(1–84)*

Mosekilde, L., Søgaard, C. H., Danielsen, C. C., Törring, O., & NILSSON, M. H. L. (1991) · Endocrinology · doi:10.1210/endo-129-1-421 · Cited by 180 · see citing works

Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.

Cao, J., Venton, L., Sakata, T., & Halloran, B. P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.270 · Cited by 173 · see citing works

Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.

Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11150 · Cited by 150 · see citing works

Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis

Mizuno, A., Kanno, T., HOSHI, M., Shibata, O., Yano, K., Fujise, N., Kinosaki, M., Yamaguchi, K., Tsuda, E., Murakami, A., et al. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740200049 · Cited by 146 · see citing works

Soluble RANKL and risk of nontraumatic fracture.

Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146 · see citing works

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140 · see citing works

The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis

Fazzalari, N. L., Kuliwaba, J. S., Atkins, G. J., Forwood, M. R., & Findlay, D. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1015 · Cited by 129 · see citing works

Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107 · see citing works

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103 · see citing works

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97 · see citing works

Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.

Li, C. Y., Price, C., Delisser, K., Nasser, P., Laudier, D., Clement, M., Jepsen, K. J., & Schaffler, M. B. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041010 · Cited by 96 · see citing works

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.

Kostenuik, P. J., Bolon, B., Morony, S., Daris, M., Geng, Z., Carter, C., & Sheng, J. (2004) · Bone · doi:10.1016/j.bone.2003.12.006 · Cited by 82 · see citing works

Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Buxton, E. C., Yao, W., & Lane, N. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032066 · Cited by 79 · see citing works

Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.

Mosekilde, L., Thomsen, J. S., Mackey, M. S., & Phipps, R. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00375-6 · Cited by 78 · see citing works

Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.

Kodama, Y., Nakayama, K., Fuse, H., Fukumoto, S., Kawahara, H., Takahashi, H., Kurokawa, T., Sekiguchi, C., Nakamura, T., & Matsumoto, T. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.7.1058 · Cited by 76 · see citing works

Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.

Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71 · see citing works

Hindlimb unloading has a greater effect on cortical compared with cancellous bone in mature female rats

Allen, M. R., & Bloomfield, S. A. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00656.2002 · Cited by 70 · see citing works

Osteoprotegerin mitigates tail suspension-induced osteopenia.

Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66 · see citing works

CD4 + CD45RB Hi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

Byrne, F. R., Morony, S., Warmington, K., Geng, Z., Brown, H. L., Flores, S. A., Fiorino, M., Yin, S. L., Hill, D., Porkess, V., et al. (2004) · Gut · doi:10.1136/gut.2003.035113 · Cited by 65 · see citing works

Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.

O'Brien, E. A., Williams, J. H. H., & Marshall, M. J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3129 · Cited by 61 · see citing works

Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures

Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jørgensen, H. R. I., & Abrahamsen, B. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0074-4 · Cited by 60 · see citing works

Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane

O’Brien, E. A., Williams, J. H. H., & Marshall, M. J. E. (2001) · Bone · doi:10.1016/s8756-3282(00)00431-2 · Cited by 54 · see citing works

Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism

Stilgren, L. S., Rettmer, E., Eriksen, E. F., Hegedűs, L. D., Beck‐Nielsen, H., & Abrahamsen, B. (2004) · Bone · doi:10.1016/j.bone.2004.03.012 · Cited by 53 · see citing works

Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population

Trofimov, S., Pantsulaia, I., Kobyliansky, E., & Livshits, G. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500305 · Cited by 51 · see citing works

Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins

Abrahamsen, B., Hjelmborg, J., Kostenuik, P. J., Stilgren, L. S., Kyvik, K. O., Adamu, S., Brixen, K., & Langdahl, B. L. (2005) · Bone · doi:10.1016/j.bone.2004.12.015 · Cited by 45 · see citing works

The effects of osteoprotegerin on the mechanical properties of rat bone.

Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J. (2001) · Journal of Materials Science: Materials in Medicine · doi:10.1023/a:1011229324412 · Cited by 39 · see citing works

A toxicity profile of osteoprotegerin in the cynomolgus monkey.

Smith, B. B., Cosenza, M. E., Mancini, A., Dunstan, C., Gregson, R., Martin, S. W., Smith, S. Y., & Davis, H. (2003) · International Journal of Toxicology · doi:10.1177/109158180302200512 · Cited by 33 · see citing works

Effects of aminohydroxybutane bisphosphonate on bone growth when administered after hind-limb bone loss in tail-suspended rats.

Apseloff, G., Girten, B. E., Weisbrode, S. E., Walker, M., Stern, L. S., KRECIC, M. E., & Gerber, N. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39546-7 · Cited by 31 · see citing works

Osteoclastogenesis Inhibitory Factor/Osteoprotegerin Reduced Bone Loss Induced by Mechanical Unloading

Ichinose, Y., Tanaka, H., Inoue, M., Mochizuki, S., Tsuda, E., & Seino, Y. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0028-x · Cited by 26 · see citing works

Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats.

Mochizuki, S.-I., Fujise, N., Higashio, K., & Tsuda, E. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s774-002-8441-x · Cited by 24 · see citing works

The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

Morony, S., Warmington, K. S., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M. S., Tan, H. L. E., Capparelli, C., Starnes, C. O., Dunstan, C. R., et al. (2005) · Cited by 13 · see citing works

RANKL–RANK signaling in osteoclastogenesis and bone disease

Wada, T., Nakashima, T., Nishina, H., & Penninger, J. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.11.007 · Cited by 1,207 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL

Kostenuik, P. J., Nguyen, H. Q., McCabe, J. G., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L. Z., Cattley, R., Van, G. Y., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 442 · see citing works

Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL

Sobacchi, C., Frattini, A., Guerrini, M. M., Abinun, M., Pangrazio, A., Susani, L., Bredius, R. G. M., Mancini, G. M. S., Cant, A. J., Bishop, N. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2076 · Cited by 389 · see citing works

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Papapoulos, S. E., Chapurlat, R. D., Libanati, C. R., Brandi, M. L., Brown, J. P., Czerwinski, E. J., Krieg, M.-A., Man, Z., Mellström, D., Radominski, S., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1479 · Cited by 345 · see citing works

A single-dose study of denosumab in patients with various degrees of renal impairment

Block, G. A., Bone, H. G., Fang, L., Lee, E. W., & Padhi, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1613 · Cited by 341 · see citing works

RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling

Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309 · see citing works

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

on behalf of the DAPS Investigators, Freemantle, N., Satram‐Hoang, S., Tang, E., Kaur, P. P., Macarios, D., Siddhanti, S. R., Borenstein, J. E., & Kendler, D. L. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1780-1 · Cited by 289 · see citing works

Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity

Walsh, M. C., Takegahara, N., Kim, H., & Choi, Y. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.213 · Cited by 253 · see citing works

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Bone, H. G., Chapurlat, R. D., Brandi, M. L., Brown, J. P., Czerwinski, E. J., Krieg, M.-A., Mellström, D., Radominski, S., Reginster, J., Resch, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1597 · Cited by 255 · see citing works

Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis

Deng, C., Zhang, Q., He, P., Zhou, B., He, K., Sun, X., Lei, G., Gong, T., & Zhang, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-22454-z · Cited by 252 · see citing works

The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications

Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246 · see citing works

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

Kendler, D. L., Cosman, F., Stad, R. K., & Ferrari, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01936-y · Cited by 247 · see citing works

Osteoclastogenesis--current knowledge and future perspectives.

Yavropoulou, M. P., & Yovos, J. G. (2008) · PubMed · Cited by 223 · see citing works

Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing

Gerstenfeld, L. C., Sacks, D. J., Pelis, M., Mason, Z. D., Graves, D. T., Barrero, M., Ominsky, M. S., Kostenuik, P. J., Morgan, E. F., & Einhorn, T. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081113 · Cited by 218 · see citing works

RANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis

Jin, Q., Cirelli, J. A., Park, C. H., Sugai, J. V., Taba, M., Kostenuik, P. J., & Giannobile, W. V. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.070073 · Cited by 198 · see citing works

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

Austin, M., Yang, Y., Vittinghoff, E., Adami, S., Boonen, S., Bauer, D. C., Bianchi, G., Bolognese, M. A., Christiansen, C., Eastell, R., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1472 · Cited by 182 · see citing works

Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor κB ligand/osteoprotegerin ratio

Seriwatanachai, D., Thongchote, K., Charoenphandhu, N., Pandaranandaka, J., Tudpor, K., Teerapornpuntakit, J., Suthiphongchai, T., & Krishnamra, N. (2007) · Bone · doi:10.1016/j.bone.2007.11.008 · Cited by 176 · see citing works

The molecular mechanism behind bone remodelling: a review

Proff, P., & Römer, P. (2009) · Clinical Oral Investigations · doi:10.1007/s00784-009-0268-2 · Cited by 172 · see citing works

Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial

Jafarnejad, S., Djafarian, K., Fazeli, M. R., Yekaninejad, M. S., Rostamian, A., & Keshavarz, S. A. (2017) · Journal of the American College of Nutrition · doi:10.1080/07315724.2017.1318724 · Cited by 165 · see citing works

Bone and Bone Graft Healing

Marx, R. E. (2007) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2007.07.008 · Cited by 160 · see citing works

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

Miller, P. D., Wagman, R. B., Peacock, M., Lewiecki, E. M., Bolognese, M. A., Weinstein, R. L., Ding, B., Martín, J. S., & McClung, M. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1805 · Cited by 140 · see citing works

Clinical development of anti-RANKL therapy

Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 138 · see citing works

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Dempster, D. W., Lambing, C. L., Kostenuik, P. J., & Grauer, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.002 · Cited by 134 · see citing works

Prevention of glucocorticoid‐induced bone loss in mice by inhibition of RANKL

Hofbauer, L. C., Zeitz, U., Schoppet, M., Skalicky, M., Schüler, C., Stolina, M., Kostenuik, P. J., & Erben, R. G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24445 · Cited by 133 · see citing works

Updates on bisphosphonates and potential pathobiology of bisphosphonate‐induced jaw osteonecrosis

Sarin, J., DeRossi, S. S., & Akintoye, S. O. (2007) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01381.x · Cited by 132 · see citing works

Pathophysiological roles of osteoprotegerin (OPG)

Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 128 · see citing works

RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

Samelson, E. J., Miller, P. D., Christiansen, C., Daizadeh, N. S., Grazette, L. P., Anthony, M. S., Egbuna, O. I., Wang, A., Siddhanti, S. R., Cheung, A. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2043 · Cited by 127 · see citing works

Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

Sutjandra, L., Rodriguez, R. D., Doshi, S., Ma, M., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594240-000000000-00000 · Cited by 121 · see citing works

Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease.

van Breemen, M. V., de Fost, M., Voerman, J., Laman, J., Boot, R., Maas, M., Hollak, C., Aerts, J., & Rezaee, F. (2007) · Biochimica et Biophysica Acta · doi:10.1016/j.bbadis.2007.04.002 · Cited by 128 · see citing works

HIV‐1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFα activation

Gibellini, D., Crignis, E. D., Ponti, C., Cimatti, L., Borderi, M., Tschon, M., Giardino, R., & Re, M. C. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21266 · Cited by 110 · see citing works

Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement

Dunn, M. D., Park, C. H., Kostenuik, P. J., Kapila, S., & Giannobile, W. V. (2007) · Bone · doi:10.1016/j.bone.2007.04.194 · Cited by 109 · see citing works

Natural Products from Chinese Medicines with Potential Benefits to Bone Health

Che, C., Wong, M., & Lam, C. W. K. (2016) · Molecules · doi:10.3390/molecules21030239 · Cited by 106 · see citing works

Osteoblast extracellular Ca2+-sensing receptor regulates bone development, mineralization, and turnover

Dvorak‐Ewell, M., Chen, T., Liang, N., Garvey, C., Liu, B., Tu, C., Chang, W., Bikle, D. D., & Shoback, D. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.520 · Cited by 100 · see citing works

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

on behalf of the DAPS Investigators, Kendler, D. L., McClung, M. R., Freemantle, N., Lillestol, M. J., Moffett, A. H., Borenstein, J. E., Satram‐Hoang, S., Yang, Y., Kaur, P. P., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1378-z · Cited by 100 · see citing works

The role of osteoprotegerin in cardiovascular disease

Montagnana, M., Lippi, G., Danese, E., & Guidi, G. C. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.727019 · Cited by 98 · see citing works

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

Ominsky, M. S., Stouch, B., Schroeder, J., Pyrah, I. T. G., Stolina, M., Smith, S. Y., & Kostenuik, P. J. (2011) · Bone · doi:10.1016/j.bone.2011.04.001 · Cited by 97 · see citing works

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

Anastasilakis, A. D. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s24239 · Cited by 92 · see citing works

The role of Wnts in bone metastases

Hall, C. L., & Keller, E. T. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9022-2 · Cited by 86 · see citing works

Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss

Hsu, Y., Chen, W., Chan, C.-H., Wu, C., Sun, Z., & Chang, M. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20102234 · Cited by 86 · see citing works

Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

Pierroz, D. D., Bonnet, N., Baldock, P. A. J., Ominsky, M. S., Stolina, M., Kostenuik, P. J., & Ferrari, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.101964 · Cited by 85 · see citing works

The relationship of denosumab pharmacology and osteonecrosis of the jaws

Malan, J., Ettinger, K. S., Naumann, E., & Beirne, O. R. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2012.08.439 · Cited by 83 · see citing works

C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and – independent pathways

Agoston, H., Khan, S. M., James, C. G., Gillespie, J. R., Serra, R. A., Stanton, L., & Beier, F. (2007) · BMC Developmental Biology · doi:10.1186/1471-213x-7-18 · Cited by 82 · see citing works

Key roles of the OPG–RANK–RANKL system in bone oncology

Baud'huin, M., Duplomb, L., Velasco, C. R., Fortun, Y., Heymann, D., & Padrines, M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.221 · Cited by 87 · see citing works

A comprehensive review of denosumab for bone metastasis in patients with solid tumors

Gül, G., Şendur, M. A. N., Aksoy, S., Sever, A. R., & Altundağ, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1105795 · Cited by 79 · see citing works

Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells

Li, F., Yang, Y., Zhu, P., Chen, W., Qi, D., Shi, X., Zhang, C.-F., Yang, Z., & Li, P. (2012) · Fitoterapia · doi:10.1016/j.fitote.2012.08.008 · Cited by 79 · see citing works

Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis

Ta, H. M., Nguyen, G. T. T., Jin, H. M., Choi, J., Park, H., Kim, N., Hwang, H., & Kim, K. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011686107 · Cited by 78 · see citing works

Denosumab in Osteoporosis and Oncology

Burkiewicz, J. S., Scarpace, S. L., & Bruce, S. P. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m102 · Cited by 76 · see citing works

Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients

Marathe, A., Peterson, M. C., & Mager, D. E. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137703 · Cited by 75 · see citing works

Correlation between osteoporosis and cardiovascular disease

Sprini, D. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.2.117 · Cited by 75 · see citing works

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin

Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q., Asuncion, F., Tan, H., Grisanti, M. S., Dwyer, D., et al. (2009) · Bone · doi:10.1016/j.bone.2009.06.011 · Cited by 67 · see citing works

Osteoporosis and cardiovascular disease: an update

Lello, S., Capozzi, A., & Scambia, G. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1041908 · Cited by 67 · see citing works

Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures

Kumar, S., Wang, M., Kim, A. S., McDonald, M. M., & Girgis, C. M. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf037 · Cited by 68 · see citing works

Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate

Stefanik, D. J., Sarin, J., Lam, T., Levin, L. M., Leboy, P. S., & Akintoye, S. O. (2007) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01402.x · Cited by 66 · see citing works

p ‐Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model

Neog, M. K., Pragasam, S. J., Krishnan, M., & Rasool, M. (2017) · BioFactors · doi:10.1002/biof.1377 · Cited by 65 · see citing works

The Effect of RANKL/OPG Balance on Reducing Implant Complications

Kapasa, E., Giannoudis, P. V., Jia, X., Hatton, P. V., & Yang, X. (2017) · Journal of Functional Biomaterials · doi:10.3390/jfb8040042 · Cited by 64 · see citing works

New molecular targets in bone metastases

Santini, D., Galluzzo, S., Zoccoli, A., Pantano, F., Fratto, M. E., Vincenzi, B., Lombardi, L., Gucciardino, C., Silvestris, N., Riva, E., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70013-x · Cited by 63 · see citing works

Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial

Napoli, N., Pannacciulli, N., Vittinghoff, E., Crittenden, D. B., Yun, J., Wang, A., Wagman, R. B., & Schwartz, A. V. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2991 · Cited by 63 · see citing works

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.

Owen, S., Ye, L., Sanders, A. J., Mason, M. D., & Jiang, W. G. (2013) · PubMed · Cited by 58 · see citing works

RANKL/RANK as Key Factors for Osteoclast Development and Bone Loss in Arthropathies

Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0298-6_7 · Cited by 54 · see citing works

Local osteoprotegerin gene transfer inhibits relapse of orthodontic tooth movement

Zhao, N., Lin, J., Kanzaki, H., Ni, J., Chen, Z., Liang, W., & Liu, Y. (2011) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2011.06.035 · Cited by 53 · see citing works

Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway

Liu, W. X., Xu, C., Zhao, H., Xia, P., Song, R., Gu, J., Liu, X., Bian, J., Yuan, Y., & Liu, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142519 · Cited by 53 · see citing works

Salidroside Improves Bone Histomorphology and Prevents Bone Loss in Ovariectomized Diabetic Rats by Upregulating the OPG/RANKL Ratio

Zheng, H., Qi, S., & Chen, C. (2018) · Molecules · doi:10.3390/molecules23092398 · Cited by 52 · see citing works

The Long and the Short of Bone Therapy

Whyte, M. P. (2006) · New England Journal of Medicine · doi:10.1056/nejme068003 · Cited by 52 · see citing works

Prolactin decreases the expression ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin in human fetal osteoblast cells

Seriwatanachai, D., Charoenphandhu, N., Suthiphongchai, T., & Krishnamra, N. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.04.026 · Cited by 50 · see citing works

Skeletal and extraskeletal actions of denosumab

Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 48 · see citing works

The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial

Hooshmand, S., Brisco, J. R. Y., & Arjmandi, B. H. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514000671 · Cited by 48 · see citing works

Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma

Lamoureux, F., Picarda, G. G. A., Rousseau, J., Gourden, C., Battaglia, S., Charrier, C., Pitard, B., Heymann, D., & Rédiní, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0497 · Cited by 47 · see citing works

The role of stromal cells in inflammatory bone loss

Wehmeyer, C., Pap, T., Buckley, C., & Naylor, A. (2017) · Clinical and Experimental Immunology · doi:10.1111/cei.12979 · Cited by 43 · see citing works

Osteoblasts express claudins and tight junction-associated proteins

Wongdee, K., Pandaranandaka, J., Teerapornpuntakit, J., Tudpor, K., Thongbunchoo, J., Thongon, N., Jantarajit, W., Krishnamra, N., & Charoenphandhu, N. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0419-6 · Cited by 46 · see citing works

Denosumab update

Lewiecki, E. M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832ca41c · Cited by 45 · see citing works

Osteoprotegerin Lys3Asn Polymorphism and the Risk of Fracture in Older Women

Moffett, S. P., Oakley, J. I., Cauley, J. A., Lui, L.-Y., Ensrud, K. E., Taylor, B. C., Hillier, T. A., Hochberg, M., Li, J., Cayabyab, S., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1019 · Cited by 44 · see citing works

MicroRNA‐155 inhibition up‐regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate‐treated osteoporotic mice

Mao, Z., Zhu, Y., Hao, W., Chu, C., & Su, H. (2019) · IUBMB Life · doi:10.1002/iub.2131 · Cited by 44 · see citing works

Absence of ERRα in Female Mice Confers Resistance to Bone Loss Induced by Age or Estrogen-Deficiency

Teyssier, C., Gallet, M., Rabier, B., Monfoulet, L., Dine, J., Macari, C., Espallergues, J., Horard, B., Giguère, V., Cohen-Solal, M. E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007942 · Cited by 44 · see citing works

Juvenile Paget's Disease: The Second Reported, Oldest Patient Is Homozygous for the TNFRSF11B “Balkan” Mutation (966_969delTGACinsCTT), Which Elevates Circulating Immunoreactive Osteoprotegerin Levels

Whyte, M. P., Singhellakis, P. N., Petersen, M. B., Davies, M., Totty, W. G., & Mumm, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070307 · Cited by 42 · see citing works

Denosumab reduces early migration in total knee replacement

Ledin, H., Good, L., & Aspenberg, P. (2017) · Acta Orthopaedica · doi:10.1080/17453674.2017.1300746 · Cited by 43 · see citing works

One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

Ominsky, M. S., Stolina, M., Li, X., Corbin, T. J., Asuncion, F., Barrero, M., Niu, Q., Dwyer, D., Adamu, S., Warmington, K. S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090215 · Cited by 42 · see citing works

Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis

Lyritis, G. P., Γεωργούλας, Θ., & Zafeiris, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05666.x · Cited by 39 · see citing works

Preconception endurance training with voluntary exercise during pregnancy positively influences on remodeling markers in female offspring bone

Gaeini, A. A., Neek, L. S., Choobineh, S., Eslaminejad, M. B., Satarifard, S., Sayahpour, F. A., & Mousavi, S. N. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2016.1140140 · Cited by 38 · see citing works

Locally limited inhibition of bone resorption and orthodontic relapse by recombinant osteoprotegerin protein

Schneider, D. A., Smith, S. M., Campbell, C. R., Hayami, T., Kapila, S., & Hatch, N. E. (2015) · Orthodontics and Craniofacial Research · doi:10.1111/ocr.12086 · Cited by 38 · see citing works

Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis

Samara, S., Dailiana, Z. H., Chassanidis, C., Koromila, T., Papatheodorou, L. K., Malizos, Κ. Ν., & Κollia, P. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.10.014 · Cited by 37 · see citing works

Animal models of osteogenesis imperfecta: applications in clinical research

Carriero, A., Enderli, T., Burtch, S. R., & Templet, J. (2016) · Orthopedic Research and Reviews · doi:10.2147/orr.s85198 · Cited by 36 · see citing works

Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study

Forte, L., Torricelli, P., Boanini, E., Gazzano, M., Fini, M., & Bigi, A. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.02.040 · Cited by 36 · see citing works

Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis

Messex, J. K., & Liou, G. (2023) · Life · doi:10.3390/life13020333 · Cited by 36 · see citing works

The endocrine disruptor cadmium alters human osteoblast-like Saos-2 cells homeostasis in vitro by alteration of Wnt/β-catenin pathway and activation of caspases

Papa, V., Bimonte, V. M., Wannenes, F., d’Abusco, A. S., Fittipaldi, S., Scandurra, R., Politi, L., Crescioli, C., Lenzi, A., Luigi, L. D., et al. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0380-x · Cited by 36 · see citing works

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

Morrissey, C. M., Kostenuik, P. J., Brown, L. G., Vessella, R. L., & Corey, E. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-148 · Cited by 36 · see citing works

Premetastatic niche: ready for new therapeutic interventions?

Zoccoli, A., Iuliani, M., Pantano, F., Imperatori, M., Intagliata, S., Vincenzi, B., Marchetti, P., Papapietro, N., Denaro, V., Tonini, G., et al. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.656092 · Cited by 35 · see citing works

Denosumab: recent update in postmenopausal osteoporosis.

da Silva, I. S., & Branco, J. (2012) · PubMed · Cited by 33 · see citing works

Lactation induces increases in the RANK/RANKL/OPG system in maxillary bone

Macari, S., Sharma, L. A., Wyatt, A. K., da Silva, J. M., Dias, G. J., Silva, T. A., Szawka, R. E., & Grattan, D. R. (2018) · Bone · doi:10.1016/j.bone.2018.01.032 · Cited by 34 · see citing works

Further Insights in the Mechanisms of Interleukin-1β Stimulation of Osteoprotegerin in Osteoblast-Like Cells

Lambert, C., Oury, C., Dejardin, E., Chariot, A., Piette, J. G., Malaise, M., Merville, M., & Franchimont, N. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070508 · Cited by 33 · see citing works

The RANKL Pathway and Denosumab

Dore, R. K. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.07.004 · Cited by 33 · see citing works

Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis

Hsu, Y., Chiu, Y.-S., Chen, W., Huang, K., Jou, I., Wu, P.-T., Wu, C., & Chang, M. (2016) · Scientific Reports · doi:10.1038/srep24339 · Cited by 33 · see citing works

RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis

Verdrengh, M., Bokarewa, M. I., Ohlsson, C., Stolina, M., & Tarkowski, A. (2009) · Bone · doi:10.1016/j.bone.2009.10.028 · Cited by 32 · see citing works

Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study

Campbell, G. M., Ominsky, M. S., & Boyd, S. K. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1283-5 · Cited by 31 · see citing works

Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats

Charoenphandhu, N., Teerapornpuntakit, J., Methawasin, M., Wongdee, K., Thongchote, K., & Krishnamra, N. (2008) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y08-037 · Cited by 31 · see citing works

Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts

Akiyama, T., Dass, C. R., Shinoda, Y., Kawano, H., Tanaka, S., & Choong, P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.62.04.0009 · Cited by 30 · see citing works

RANKL signaling in bone physiology and cancer

Dougall, W. C. (2007) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282f335be · Cited by 30 · see citing works

Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis

Törring, O. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15579189 · Cited by 30 · see citing works

RANKL inhibition: a promising novel strategy for breast cancer treatment

González‐Suárez, E. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0646-5 · Cited by 29 · see citing works

Inhibition of RANK/RANKL signal transduction pathway: A promising approach for osteoporosis treatment

Bai, Y., Yang, F., Xuan, K., Bai, Y.-X., & Wu, B. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.03.021 · Cited by 28 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

Trouvin, A., & Goëb, V. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 41 · see citing works

Advances in bone biology and new treatments for bone loss

Gallagher, J. C. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.04.005 · Cited by 55 · see citing works

Regulation of receptor activator of nuclear factor-κB ligand-receptor activator of nuclear factor-κB and osteoprotegerin in bone modeling and remodeling

Wang, M. (2009) · International Journal of Stomatology

[RANKL and OPG regulation on bone remodeling].

Zhao, Y. F., Cai, Y., & Wang, Y. (2010) · PubMed · Cited by 2 · see citing works